Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

Johnson & Johnson MedTech has announced U.S. 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Using Nvidia and GE Healthcare technology, the robotic surgery system is intended to help surgeons diagnose lung cancer ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Says Mag 7 Stocks Are A Thing Of The Past. In this ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Reports Q4 revenue was $38K and $600K for the year ended December 3 compared to no revenue in the same periods in 2023. The increase in ...